WuXi Biologics (Cayman) Inc. (2269.HK) HKSE
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
WuXi Biologics (Cayman) Inc.
Address
No. 108, Meiliang Road
Wuxi, JS 214092
China
Phone
86 51081831205
Sector
Healthcare
Industry
Biotechnology
Employees
14705
First IPO Date
June 13, 2017
Key Executives
| Name | Title | Pay | Year Born |
| Zhisheng Chen | Chief Executive Officer & Executive Director | 19.19M | 1973 |
| Jian Dong | Chief Executive Officer of WuXi Vaccines | 0 | 1964 |
| Xuejun Gu | CTO, Chief Client Officer, EVP of Global Biologics Development Department & Executive Director | 6.21M | 1971 |
| Jijie Gu | Chief Scientific Officer & President of Global Biologics Research | 0 | 1966 |
| He Wang | General Counsel, Chief Compliance Officer, SVP and Head of Legal & Compliance Department | 0 | N/A |
| Lihua Yu | Chief Operating Officer & Senior Vice President | 0 | N/A |
| Angus Scott Marshall Turner | Senior Vice President and Head of Global BD & Alliance Management | 0 | 1968 |
| Ming Tu | Chief Financial Officer & Executive Vice President | 0 | 1969 |
| Lina Fan | Senior Vice President & Head of Investor Relations | 0 | N/A |
| Xiaohui Liu | Executive VP & Chief Human Resources Officer | 0 | N/A |
| Ge Li | Founder & Chairman | 0 | 1967 |
Description
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
